98%
921
2 minutes
20
Objective: This study aimed to comprehensively investigate the antibiotic resistance characteristics of in chronic rhinosinusitis (CRS) patients and to identify key determinants influencing the development of methicillin-resistant Staphylococcus aureus (MRSA) infections.
Methods: A retrospective analysis was conducted on 180 CRS patients admitted to our hospital between February 2022 and July 2024. Nasal secretion samples were collected upon admission for strain isolation, and antibiotic susceptibility testing was performed using an automated microbiology system. Patients were categorized into MRSA and methicillin-sensitive Staphylococcus aureus (MSSA) groups based on oxacillin resistance. Univariate analysis was used to screen potential risk factors, followed by multivariate logistic regression to determine independent predictors.
Results: Among 180 isolated strains, 74 (41.1%) were MRSA and 106 (58.9%) were MSSA. MRSA strains exhibited significantly higher resistance rates to cefoxitin, amikacin, ciprofloxacin, and six other antibiotic classes compared to MSSA strains (all P<0.05), with resistance exceeding 50% for fluoroquinolones and macrolides. Univariate analysis identified 12 clinical factors associated with MRSA infection, including male sex, smoking history, disease duration >5 years, and frequent antibiotic use. Multivariate regression analysis confirmed nine independent risk factors: male sex (OR=2.31), nasal structural abnormalities (OR=1.89), previous nasal surgery (OR=1.76), ≥3 acute infections per year (OR=2.14), excessive antibiotic exposure, and others.
Conclusion: MRSA exhibits pronounced resistance to commonly used antibiotics in CRS treatment. Clinicians should prioritize targeted screening for high-risk patients, optimize antibiotic stewardship, and enhance postoperative nasal function management. Implementing a multifaceted approach-including early risk assessment, standardized antibiotic use, and intensified follow-up care-can effectively mitigate MRSA infection risks and improve overall treatment outcomes for CRS patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399101 | PMC |
http://dx.doi.org/10.2147/IDR.S546894 | DOI Listing |
Int Immunopharmacol
September 2025
ENT Institute and Department of Otorhinolaryngology, Affiliated Eye and ENT Hospital of Fudan University, Shanghai, China. Electronic address:
Background: Chronic rhinosinusitis (CRS) leads to a burden in life and economy. Better therapies need to be explored.
Objective: This stage I study aims to explore the efficacy and safety of intranasal corticosteroids combined with mucoactive drugs for CRS.
J Neurosurg
September 2025
2Latin American Neurosurgical Collaborative for Excellence in Research, Ciudad de México, México.
Objective: Open resective surgery (ORS) has become the standard of care for focal drug-resistant epilepsy (DRE). However, minimally invasive surgical alternatives, such as laser interstitial thermal therapy (LITT), have also been shown to be safe and effective. A meta-analysis comparing both treatments is warranted to assess the benefits of each modality for focal DRE.
View Article and Find Full Text PDFInt Forum Allergy Rhinol
September 2025
Division of Otolaryngology Head & Neck Surgery, University of British Columbia, Vancouver, British Columbia, Canada.
Background: Emerging evidence suggests a possible link between rhinosinusitis and systemic rheumatic diseases; however, no meta-analysis has comprehensively examined this association to date. We aimed to investigate if patients with rhinosinusitis have a predisposition to unmasking rheumatic diseases compared to individuals without rhinosinusitis.
Methods: A comprehensive search in MEDLINE, Embase, Cochrane Library, and Web of Science was conducted until February 2025 for studies characterizing rheumatic disease incidence, prevalence, and risk in cohorts of rhinosinusitis patients.
Front Microbiol
August 2025
Institute of Tuberculosis Prevention and Control, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, China.
Background: The urinary lipoarabinomannan (LAM) assay has emerged as a promising tool for tuberculosis (TB) diagnosis and treatment monitoring. This study aimed to evaluate the diagnostic and monitoring performance of LAM compared to Acid-fast bacilli (AFB), Mycobacteria Growth Indicator Tube (MGIT), and GeneXpert, and to establish its clinical utility in a stratified TB population.
Methods: A prospective cohort study included TB patients stratified by AFB/MGIT status into three groups.
Z Rheumatol
September 2025
Medizinische Klinik 3 - Rheumatologie und Immunologie, Friedrich-Alexander-Universität Erlangen-Nürnberg und Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Deutschland.
Background: Chimeric antigen receptor T-cells (CAR T-cells) are an effective therapeutic approach in the treatment of B-cell driven malignancies. In addition to malignant B-cells, autoreactive B-cells are important targets for CD19 CAR T-cells, as they are a source of autoantibody production and support both the onset and progression of systemic lupus erythematosus (SLE). We and others have shown that their use in severe and therapy-refractory cases of SLE is effective and, moreover, safe.
View Article and Find Full Text PDF